eIF2B Modulators Resolve ISR-Translation Trade-off
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies fail to effectively modulate the integrated stress response (ISR) pathway, particularly in addressing diseases associated with eIF2α phosphorylation and impaired eIF2B activity, which are linked to various conditions such as neurodegenerative diseases, cancer, and metabolic disorders.
Innovation Solution
Development of compounds, such as those represented by Formula (I), which act as eIF2B modulators to activate eIF2B and attenuate the ISR signaling pathway, thereby treating diseases like neurodegenerative disorders, cancer, and metabolic diseases by influencing eIF2α phosphorylation and eIF2B activity levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If eIF2α is phosphorylated to activate the ISR pathway, then cell stress response is improved, but translation initiation is inhibited
Solution Approach 1:
The patent modifies the chemical structure of eIF2B modulators by changing parameters such as the bridged bicyclic cycloalkyl group (D), heteroaryl substituents (A, W), and linking groups (L1, L2) to optimize the balance between stress response activation and translation initiation maintenance
Solution Approach 2:
The patent introduces eIF2B as an intermediary target that mediates between the phosphorylated eIF2α and the translation initiation process, using modulators to regulate eIF2B's guanine nucleotide exchange factor activity and thereby control the ISR pathway output
2Productivity
If eIF2B activity is increased to enhance translation, then protein synthesis is improved, but ISR pathway attenuation is reduced
Solution Approach 1:
The patent optimizes the chemical parameters of eIF2B modulators, including the bridged bicyclic cycloalkyl group (D), heteroaryl substituents (A, W), and linking groups (L1, L2), to achieve the desired balance between protein synthesis and ISR pathway function
Solution Approach 2:
The patent aims to dynamically regulate eIF2B activity through reversible binding of modulators, allowing the system to adapt between high protein synthesis mode and ISR pathway activation mode depending on cellular conditions
3Adaptability or versatility
If small molecule therapeutics are developed to modulate eIF2B, then disease treatment potential is improved, but compound complexity increases
Solution Approach 1:
The patent designs a universal scaffold structure for eIF2B modulators that can potentially treat multiple diseases (neurodegenerative, cancer, metabolic) by adjusting specific substituents (D, A, W, L1, L2) while maintaining the core eIF2B binding and activating function
Solution Approach 2:
The patent systematically varies chemical parameters such as the bridged bicyclic cycloalkyl group (D), heteroaryl substituents (A, W), and linking groups (L1, L2) to optimize the balance between therapeutic efficacy and structural complexity for different disease indications
Data Source
AI summary
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.